A new treatment is showing promise for people with high-risk smoldering multiple myeloma (SMM). This precancerous condition can progress to active multiple myeloma, a type of blood cancer. High-risk ...
A new treatment is showing promise for people with high-risk smoldering multiple myeloma (SMM). This precancerous condition ...
The phase 3 AQUILA study showed a 63.1% progression-free rate at 5 years with daratumumab versus 40.8% with active monitoring ...
"This study provides strong evidence for the use of daratumumab as a treatment for high-risk smoldering multiple myeloma," says Dr. Rajkumar, the Edward W. and Betty Knight Scripps Professor of ...
An expanded analysis from the phase 3 CEPHEUS trial showed that daratumumab plus VRd improved MRD responses as well as ...
Treatment with subcutaneous daratumumab significantly improved progression-free survival in patients with intermediate- or high-risk smoldering multiple myeloma.
GSK's Blenrep combo demonstrates significant survival benefits and improved efficacy in relapsed multiple myeloma compared to ...
British drugmaker GSK said on Monday its experimental cancer drug Blenrep in combination with other treatments reduced the ...
The progression-free survival (PFS) rate at 5 years improved from 40.8% with active monitoring and no disease-specific ...
Saad Z. Usmani, MD, MBA, FACP, FASCO, discusses the CEPHEUS trial results and impact on frontline treatment in ...
Belantamab Mafodotin shows significant OS benefit, reducing the risk of death by 42% in multiple myeloma at or after first ...
Abstracts presented Saturday at the American Society of Hematology in San Diego, California included studies on access to ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback